

NEWRON PHARMACEUTICALS SPA

ISIN: IT0004147952 WKN: 2791431 Asset Class: Stock

Company



2024/07/17 17:30:08

Price

8.33 CHF

Difference 0.12% (0.01)



Contact Details

NEWRON PHARMACEUTICALS
SPA

Tel: +39-02-610-3461

--

Fax: +39-02-610-34654

via Antonio Meucci 3

Web:

<https://www.newron.com/>

20091 Bresso

E-mail: info@newron.com

Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|--------------------------------|------------|------------------------|------------|------------------------|------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 18,271,000 | | 28,134,000 | | 40,852,000 | |
| Common stock capital | | 3,318,000 | | 3,524,000 | | 3,698,000 |
| Fixed assets | 5,777,000 | | 8,592,000 | | 11,458,000 | |
| Equity capital of a company | | -27,806,000 | | -13,853,000 | | 3,219,000 |
| Cash and cash equivalents | 5,892,000 | | 13,255,000 | | 25,923,000 | |
| Accrued liabilities | | 383,000 | | 468,000 | | 602,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 26,893,000 | | 4,977,000 | | 3,786,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 24,961,000 | | 45,602,000 | | 45,306,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 439,000 | | 217,000 | | 220,000 |
| Total assets | 24,048,000 | 24,048,000 | 36,727,000 | 36,727,000 | 52,311,000 | 52,311,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|----------|----------|-----------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | - | - | - |
| Equity ratio | -115.63% | -37.72% | 6.15% |
| Debt-equity ratio | -186.49% | -365.11% | 1,524.91% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|--------|
| Tax Expense Rate | -0.15% | -0.12% | -0.11% |

NEWRON PHARMACEUTICALS SPA

ISIN: IT0004147952 WKN: 2791431 Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| Turnover | 8,799,000 | 6,116,000 | 6,226,000 |
| Net income | -15,762,000 | -17,558,000 | -16,102,000 |
| EBIT | -11,532,721 | -13,550,590 | -13,267,177 |
| Operating income before taxes | -15,739,000 | -17,537,000 | -16,084,000 |
| Cash Flow | -9,851,000 | -11,133,000 | -12,367,000 |
| Net interest income | -4,478,000 | -4,307,000 | -3,130,000 |
| Research and development expenses | 12,710,000 | 11,981,000 | 11,522,000 |
| Income taxes | 23,000 | 21,000 | 18,000 |
| Result from investments in subsidiaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | - | - | - |

Board of Directors

| | |
|------------------|-------------------------------|
| Ulrich Köstlin | Chairman of Supervisory Board |
| Luca Benatti | Member of Supervisory Board |
| Patrick Langlois | Member of Supervisory Board |
| Gillian Dines | Member of Supervisory Board |
| Margarita Chavez | Member of Supervisory Board |

Members of Management Board

| | |
|------------------|-------------------------------|
| Stefan Weber | Chairman of Managing Board |
| Dennis Dionne | Member of Executive Committee |
| Filippo Moriggia | Member of Executive Committee |
| Laura Faravelli | Member of Executive Committee |
| Ravi Anand | Member of Executive Committee |
| Roberto Galli | Member of Executive Committee |